secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001140361-24-010100
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics CFO Brian Lenz steps down; CEO Grossman named interim CFO
------------------------------------------------------------------------

- CFO Brian Lenz transitions to consulting role effective April 1, 2024; consulting agreement through March 31, 2025.
- CEO Adam Grossman appointed Interim CFO; executive search initiated for permanent replacement.
- Grossman's 2024 base salary set at $800,000; awarded 557,728 RSUs and options for 870,950 shares at $5.40.
- Lenz receives $334,875 cash bonus for 2023 performance (141% of corporate goals achieved).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124010100/0001140361-24-010100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124010100/ef20022642_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-010100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer